Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Chemoresistance is a disturbing barrier in cancer therapy, which always results in limited therapeutic options and unfavorable prognosis. Nuclear factor E2-related factor 2 (NRF2) controls the expression of genes encoding cytoprotective enzymes and transporters that protect against oxidative stress and electrophilic injury to maintain intrinsic redox homeostasis. However, recent studies have demonstrated that aberrant activation of NRF2 due to genetic and/or epigenetic mutations in tumor contributes to the high expression of phase I and phase II drug-metabolizing enzymes, phase III transporters, and other cytoprotective proteins, which leads to the decreased therapeutic efficacy of anticancer drugs through biotransformation or extrusion during chemotherapy. Therefore, a better understanding of the role of NRF2 in regulation of these enzymes and transporters in tumors is necessary to find new strategies that improve chemotherapeutic efficacy. In this review, we summarized the recent findings about the chemoresistance-promoting role of NRF2, NRF2-regulated phase I and phase II drug-metabolizing enzymes, phase III drug efflux transporters, and other cytoprotective genes. Most importantly, the potential of NRF2 was proposed to counteract drug resistance in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 1×
“In addition, some studies indicated that oncogenic K-Ras, B-Raf and c-Myc could induce the transcription of NRF2 (DeNicola et al., 2011).”
BackgroundMoi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 3×
“sion in developing erythroid cells (Moi et al., 1994).”
BackgroundMolecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478 · cited 3×
“Additionally, Keap-Cul3 dissociation mechanism is also discovered to regulate NRF2 during this process (Baird & Dinkova-Kostova, 2011; McMahon et al., 2006; Taguchi et al., 2011), in which electrophilic and oxidative stressors dissociated KEAP1 with Cul3-based ubiquitin E3 ligase.”
BackgroundNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“Recent studies found it essential in protection against oxidative stress and apoptosis in tumor development and progression because tumor cells need enough energy for their proliferation and invasion (Mitsuishi et al., 2012).”
BackgroundRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“Epigenetic and post-translational modifications of KEAP1 (Ooi et al., 2011; Sporn & Liby, 2012) and increasing disruptor proteins such as p62 (Ryoo et al., 2015) also disrupt their interact and the inhibitory effect of KEAP1 on NRF2.”
BackgroundDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“Studies in past few years also discovered some somatic mutations in KEAP1 (Ohta et al., 2008; Singh et al., 2006; Takahashi et al., 2010).”
BackgroundTebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837 · cited 1×
“AKR genes that contain ARE sequences in their flanking regions have been reviewed by Tebay et al. (2015) and are listed in Table 1.”
BackgroundSmall Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760 · cited 1×
“This means that the specificity, bioactivity and mechanism of these inhibitors cannot be ensured because most of them are nonspecific electrophiles with off-target effects (Magesh et al., 2012).”
BackgroundTong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 1×
“…Neh2 has two binding sites called DLG and ETGE that bind with Kelch-like ECH-associated protein 1 (KEAP1) (Fukutomi et al., 2014; McMahon et al., 2006; Tong et al., 2006), a negative regulator of NRF2 by recruiting Cullin E3 ubiquitin ligase (Cul3)-based ubiquitin E3 ligase (Ogura et al., 2010).”
BackgroundRada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 1×
“Neh6 has DSGIS and DSAPGS motifs that bind with b-transducin repeatcontaining protein (b-TrCP) which can negatively regulate NRF2 by recruiting S-phase kinase-associated protein 1 (Skp1)–Cul1–Rbx1 or Roc1 core E3 ubiquitin ligase (Chowdhry et al., 2013; Rada et al., 2011, 2012; Wu et al., 2003).”
BackgroundStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 1×
“There are many other factors leading to NRF2 upregulation in lung cancer issues, including single nuclear polymorphism (SNP) (Marzec et al., 2007), somatic mutation (Padmanabhan et al., 2006), epigenetic regulation (Muscarella et al., 2014) and post-transcriptional modification (Kawai et al., 2011).”
BackgroundBrusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
Structure of a β-TrCP1-Skp1-β-Catenin Complex
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., & Pavletich, N. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00234-x · Cited by 612
Human cytochromes P450 in health and disease
Nebert, D. W., Wikvall, K., & Miller, W. L. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0431 · Cited by 505 · cited 1×
“As a monooxygenases, CYP1B1 mainly metabolizes 17bestradiol and foreign chemicals including chemotherapeutic drugs, such as cyclophosphamide and taxanes, through hydroxylation (Lewis, 2004; Nebert et al., 2013).”
BackgroundDhakshinamoorthy, S., Jain, A. K., Bloom, D. A., & Jaiswal, A. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500166200 · Cited by 414 · cited 1×
“…regulation of NRF2, including E-cadherin (Kim et al., 2012), activating transcription factor-3 (ATF3) (Brown et al., 2008), tumor protein P53 (Faraonio et al., 2006), BTB and CNC homology 1 (bach1) (Dhakshinamoorthy et al., 2005), caveolin-1 (Li et al., 2012), and GSK3 (Chowdhry et al., 2013).”
BackgroundOoi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401 · cited 1×
“Epigenetic and post-translational modifications of KEAP1 (Ooi et al., 2011; Sporn & Liby, 2012) and increasing disruptor proteins such as p62 (Ryoo et al., 2015) also disrupt their interact and the inhibitory effect of KEAP1 on NRF2.”
BackgroundRushworth, S. A., Zaitseva, L., Murray, M. Y., Shah, N. M., Bowles, K. M., & MacEwan, D. J. (2012) · Blood · doi:10.1182/blood-2012-04-422121 · Cited by 290
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases
Chen, Z., & Tiwari, A. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08235.x · Cited by 274
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment
Moon, E. J., & Giaccia, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.009 · Cited by 160 · cited 1×
“2016 Informa UK Limited, trading as Taylor & Francis Group It belongs to CNC family which also includes nuclear factor erythroid-derived 2 (NF-E2), NF-E2-related-1 (NRF1), NRF3, broad complex–tramtrack–bric-a-brac (BTB) and CNC homology 1 (BACH1), and BACH2 (Chan et al., 1993; Moon & Giaccia, 2014).”
BackgroundKang, K. A., Piao, M. J., Kim, K. C., Kang, H. K., Chang, W. Y., Park, I. C., Keum, Y. S., Surh, Y. J., & Hyun, J. W. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.149 · Cited by 149 · cited 2×
“…induces 1.5-fold increase on resistance of MCF7 cells to DRN compared with controls, while overexpression of dominant negative NRF2 eliminates HER2-induced drug resistance (Kang et al., 2014a), indicating that HER2-targeted therapy may be feasible for NRF2-dependent chemoresistant phenotype.”
BackgroundMethodInfluentialRushworth, S. A., Bowles, K. M., & MacEwan, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3018 · Cited by 92 · cited 2×
“…leading to its transcriptional induction (Barrera et al., 2012; Dreger et al., 2010; Ebert et al., 2011; Pullarkat et al., 2014), increased NRF2 then induces the expression of HO-1, AKRs, and NQO1 and protects acute myeloid leukemia cells from bortezomib-induced apoptosis (Rushworth et al., 2011).”
BackgroundMutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer
Takahashi, T., Sonobe, M., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Nagai, S., Sato, K., Miyahara, R., Okubo, K., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21520 · Cited by 78
Cited by
Nrf2-Keap1 signaling in oxidative and reductive stress
Bellezza, I., Giambanco, I., Minelli, A., & Donato, R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.02.010 · Cited by 2,053
Tu, W., Wang, H., Li, S., Liu, Q., & Sha, H. (2019) · Aging and disease · doi:10.14336/ad.2018.0513 · Cited by 707
Sivandzade, F., Prasad, S., Bhalerao, A., & Cucullo, L. (2019) · Redox Biology · doi:10.1016/j.redox.2018.11.017 · Cited by 639
Nrf2–ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms
Shaw, P., & Chattopadhyay, A. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29219 · Cited by 431
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Kim, S. J., Kim, H. S., & Seo, Y. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5381692 · Cited by 406
Metadata
- Authors
- Bai, X., Chen, Y., Hou, X., Huang, M., & Jin, J.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2016-06-20
- Volume
- 48
- Issue
- 4
- Pages
- 541-567
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2463082079
- Cited by
- 157
- References
- 25
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.